ATR-mediated Proteome Remodeling is a Major Determinant of Homologous Recombination Capacity in Cancer Cells

ABSTRACT: DMSO or 5uM ATR inhibitor(VE-821) were treated for 8 days on U2OS cells prior to anlaysis.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Osteoblast

DISEASE(S): Bone Osteosarcoma

SUBMITTER: Dongsung Kim  

LAB HEAD: Marcus Smolka

PROVIDER: PXD010223 | Pride | 2018-07-17

REPOSITORIES: Pride